Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2020-07-16 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in 'Business Standard' ....
Regulatory Filings
2020-07-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE Limited and National Stock Exchange of India Limited) regarding a newspaper advertisement published pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It states that the advertisement is enclosed for information and record. There is no indication of financial data, report content, or detailed disclosures beyond the announcement of the advertisement publication. The document length is 4742 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an announcement related to regulatory compliance and publication of an advertisement, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-07-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving Import and Market Permission (Form CT-20) from the Drugs Controller General of India for a pharmaceutical product. The content is an announcement of a regulatory approval related to product marketing, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content. The document length is short (1565 characters) and serves as an official announcement to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-07-04 English
This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller ....
Regulatory Filings Classification · 95% confidence The document is a short announcement informing stock exchanges about AstraZeneca Pharma India Limited receiving Import and Market Permission (Form CT-20) from the Drugs Controller General of India for a pharmaceutical product. It is a regulatory update related to marketing authorization, not a financial report, management change, or shareholder meeting material. The document length is only 1565 characters, and it serves as a notification to the exchanges rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-04 English
Pursuant to Regulation 30 read with Part A of Schedule III, we enclose the resolutions passed by the Shareholders of the Company approving the alteration of: (a) Memorandum and Articles ....
Governance Information Classification · 95% confidence The document is a formal communication from AstraZeneca Pharma India Limited to stock exchanges regarding the alteration of the company's Memorandum and Articles of Association. It includes certified true copies of shareholder resolutions passed through postal ballot approving these alterations, detailed explanations pursuant to the Companies Act, 2013, and the revised Memorandum and Articles of Association themselves. The content focuses on corporate governance documents and changes to the company's constitutional documents rather than financial results, management changes, or other report types. This type of filing is best classified under Governance Information (CGR), as it details the company's internal rules and governance structure changes.
2020-06-29 English
Amendment to AOA/MOA
Board/Management Information Classification · 95% confidence The document is a detailed communication from AstraZeneca Pharma India Limited to stock exchanges regarding the alteration of the company's Memorandum and Articles of Association. It includes certified true copies of shareholder resolutions passed through postal ballot, explanatory statements pursuant to the Companies Act, 2013, and the revised Memorandum and Articles of Association themselves. The content focuses on corporate governance changes, specifically amendments to foundational company documents approved by shareholders. There is no financial data, earnings information, or audit content. The document is not a report publication announcement since it contains the full resolutions and explanatory statements, not just a notice of report availability. It is not a proxy solicitation or voting results announcement, but rather a formal disclosure of board and shareholder-approved changes to governance documents. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it relates to changes in company governance documents approved by shareholders and communicated to regulators and exchanges.
2020-06-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.